New research from University of Manchester experts suggests that introducing a UK-wide self-sampling program alongside existing ‘smear tests’ could help to remove most of the current barriers to cervical screening.
Marea Therapeutics launches with $190M, seeing a ‘fixable problem’ in a neglected cardiometabolic target
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS